Following positive Phase 2 trial data, the FDA granted Gilead Sciences’ Tecartus priority review for the treatment of adult acute lymphoblastic leukemia (ALL). The initial target date for the decision is Oct. 1. If approved, Tecartus will have to go up against Novartis’ CAR-T therapy, Kymriah, which was first approved for ALL in 2017. Under the medical benefit, Kymriah is covered for 88% of all insured lives.
SOURCE: MMIT Analytics, as of 6/9/21